The short answer
Richie and colleagues published a randomised controlled trial of oral glutathione supplementation on body stores in the European Journal of Nutrition in 2015, reporting increases in measured stores. The question has been contested because glutathione's fate in the digestive tract is not straightforward.
Key facts
- Key trial
- Richie 2015, Eur J Nutr (PMID 24791752)
- Design
- Randomised controlled
- Endpoint
- Body glutathione stores
- Why contested
- Digestive fate and degradation
- Alternative approach
- Supplying cysteine instead
- Relevant enzyme
- Gamma-glutamyl transpeptidase
Why the question arises at all
For most nutrients the digestive tract is a solved problem. For glutathione it is not, because the tripeptide has a specific degrading enzyme (gamma-glutamyl transpeptidase) present on intestinal surfaces. Whether administered glutathione arrives intact, or is broken to its constituent amino acids and reassembled inside cells, is the substance of the disagreement.
What the randomised trial reported
Richie and colleagues ran a randomised controlled trial on body glutathione stores, published in the European Journal of Nutrition in 2015. It is the trial the field cites on this question, and it reported increases in measured stores with supplementation. Randomised and controlled is the right design for the question.
Research material referenced
Glutathione 1500mg, third-party HPLC tested
The interpretive complication
Increased body stores can arise two ways. Intact glutathione may be absorbed and distributed. Or it may be degraded to glutamate, cysteine and glycine, absorbed as amino acids, and rebuilt. In that case the useful contribution is mainly the cysteine, and the tripeptide is an expensive way to deliver it. A store measurement alone does not distinguish these.
Why cysteine is the alternative
Since cysteine availability usually limits glutathione synthesis, supplying cysteine addresses the actual constraint and works with the cell's regulated pathway rather than around it. This is why cysteine-donor approaches have been pursued as an alternative, and it is a real argument rather than a marketing position.
The parallel with NAD+
The same structural question as the NAD+ category on this site: does supplying the finished molecule work, or does it succeed only by being degraded to precursors the cell can use? For NAD+ the answer is fairly clearly the latter. For glutathione it is less settled, and the randomised evidence is better.
What is not claimed
That glutathione supplementation produces any health outcome. Raising a measured store is a biomarker result, not a clinical one, and the same gap applies here as everywhere else on this site.
Frequently asked questions
Does oral glutathione work?
Richie 2015, a randomised controlled trial, reported increases in body stores. Whether that reflects intact absorption or degradation and resynthesis is less clear.
Why is it contested?
Gamma-glutamyl transpeptidase on intestinal surfaces degrades glutathione, so its digestive fate is not straightforward.
Why supply cysteine instead?
Cysteine availability usually limits synthesis, so supplying it addresses the actual constraint through the cell's own regulated pathway.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedRichie JP Jr et al., Randomized controlled trial of oral glutathione supplementation on body stores. Eur J Nutr 2015 (PMID 24791752)pubmed.ncbi.nlm.nih.gov
- PubMedCacciatore I et al. J Pept Sci 2004 (PMID 14994989)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · L-cysteine (CID 5862)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Glutathione articles
- Glutathione and Skin ResearchTwo 2025 systematic reviews examined glutathione for skin lightening and melasma. What they concluded, and the safety concern about intravenous use.
- Glutathione Storage and the Oxidation ProblemThe one compound in this catalogue where disulfide chemistry is a daily practical issue. Air converts GSH to GSSG, and purity does not capture it.
- Glutathione in the Published LiteratureOne of the most-studied small molecules in biology, with randomised trials and 2025 systematic reviews. How to navigate a literature this large.
- Glutathione Regulatory StatusNo marketing authorisation as a medicine. Why the cosmetic use has drawn specific regulatory attention in several jurisdictions.
- Glutathione Proposed as a Carrier, Not Just a BufferOrlowski and Meister named the gamma-glutamyl cycle in 1970 and proposed that glutathione serves a carrier function in amino acid transport.